biotech

Rotarix Rotavirus Vaccine Approved In The EU

Filed in archive Corporate and Industrial News , Drugs, Vaccines and Therapeutics , Patents and Intellectual Property Rights on March 1, 2006



The European Commission has granted approval for GlaxoSmithKline's Rotarix, making it the first rotavirus vaccine available to children in Europe for the prevention of gastroenteritis caused by rotavirus.

"European approval marks a significant milestone for the global commercialization of Rotarix(R), which has already been approved for commercial use in an additional 33 countries. It brings in a milestone payment from GSK and leads to a substantial payment of $40 million to Avant through its transaction with Paul Royalty Fund ("PRF")." In May 2005, AVANT entered into an agreement whereby an affiliate of PRF purchased an interest in the net royalties AVANT will receive on worldwide sales of Rotarix(R).


For more details of the agreement with PRF, refer to Avant Immunotherapeutics' press release.

Permalink: Rotarix Rotavirus Vaccine Approved In The EU

Tags: rotavirus  gastroenteritis  biotech  vaccine  rotarix  rotavirus+vaccine  rotarix+rotavirus  vaccine+approv 

Vote for Rotarix Rotavirus Vaccine Approved In The EU:

  • Currently 9.50/10
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
Rating: 9.50 out of 4 vote(s) cast.
 
Share It
RSSrss
Google google
Yahoo! yahoo
Addthis Subscribe using any feed reader!
Bloglines Bloglines
Most Popular   Best of   Biotech Hubs and Facilities   Biotech/Science Blogs   Corporate and Industrial News   Diagnostics, Methodologies and Instrumentation   Did you know   Drugs, Vaccines and Therapeutics   Energy, Environment and Ecology   Food and Agriculture   Gene Therapy   Genomics, Proteomics and Bioinformatics   Information About   Meetings and Other Events   Microbiology   Misc   Nanomedicine   Other Biotechnology News   Patents and Intellectual Property Rights   Quick introduction   Stem Cells